SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biogen
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
1686 75 0 BIIB
Emcee:  Harold Engstrom Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1311In fact, IM has proven not to be a problem vs. SC. Those big needles seem not tHarold Engstrom-6/21/2001
1310sc means subcutaneous (neither is oral yet) and the reason could be faster metabCacaito-6/21/2001
1309Maybe a swallowable capsule would be broken down by stomach acids; whereas, the John William Anderson-6/21/2001
1308BGEN holding up nicely prior to DNA/XOMA presentation. Both of these are down aaknahow-6/21/2001
1307BGEN held its own (+1.60%) this week ending 6-15-01 although many biotech stocksblackmerlin-6/16/2001
1306George, I didn't listen to the Amevive call and did not attend the meeting:Harold Engstrom-6/15/2001
1305Harold, did you listen to the Amevive call or the annual meeting? I just heardaknahow-6/15/2001
1304Thanks Mark. Unless they have Amevive available in s.c. form I don't think iaknahow-6/14/2001
1303Biogen moves closer to psoriasis drug OK George, you can listen to BGEN's CMark Bong-6/14/2001
1302Mark, what is the status of s.c. trials for Amevive? You thought they were doinaknahow-6/13/2001
1301Snip from article on BGEN. While the data Biogen reported appeared positive, thaknahow-6/12/2001
1300Correction. Takes 14 weeks to reach desired endpoints. Two weeks after 12 weekaknahow-6/12/2001
1299BGEN is down slightly in the pre market. Ran up about $2 but retraced the gain.aknahow-6/12/2001
1298Genentech sent out a letter to friends in the investment community about its'aknahow-6/12/2001
1297Recurrence is not an issue. Why? There are many CHRONIC conditions that requirbubbarayjr-6/11/2001
1296Mark, very interested in your thoughts on the Dr. Leonardi conference call. Arcaknahow-6/11/2001
1295Understand broker/dealer not happy that many non clients are calling the 800 numaknahow-6/11/2001
1294Dr. Leonardi psoriasis conference call. He is involved with the clinical trials aknahow-6/11/2001
1293Thanks for a balanced reply. Seems like you are correct, individuals investors aknahow-6/7/2001
1292Harold, there was an article in Barrons last weekend that compared the two psoriMark Bong-6/7/2001
1291That is a pretty harsh piece. Enough to get some Xoma investors nervous. I havHarold Engstrom-6/7/2001
1290Xoma's Potential Heartbreak of a Psoriasis Drug Delay The Street has an ambMark Bong-6/7/2001
1289Phase III Clinical Trials of Xanelim Humanized Monoclonal Antibody for Moderate-Mark Bong-5/24/2001
1288BIOGEN SAYS SERONO SIX-MONTH DATA NOT MEANINGFUL WHEN DECIDING ON LONG-TERM TRMark Bong-5/8/2001
1287What can you say to "patients treated with Rebif® have a 90% greater cHarold Engstrom-5/8/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News